Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

296 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Good manufacturing practice production of CD34+ progenitor-derived NK cells for adoptive immunotherapy in acute myeloid leukemia.
de Jonge PKJD, van Hauten PMM, Janssen LD, de Goede AL, Berrien-Elliott MM, van der Meer JMR, Mousset CM, Roeven MWH, Foster M, Blijlevens N, Hobo W, Fehniger TA, Jansen JH, Schaap NPM, Dolstra H. de Jonge PKJD, et al. Among authors: blijlevens n. Cancer Immunol Immunother. 2023 Oct;72(10):3323-3335. doi: 10.1007/s00262-023-03492-6. Epub 2023 Jul 21. Cancer Immunol Immunother. 2023. PMID: 37477653 Free PMC article.
Addition of 10-Day Decitabine to Fludarabine/Total Body Irradiation Conditioning is Feasible and Induces Tumor-Associated Antigen-Specific T Cell Responses.
Cruijsen M, Hobo W, van der Velden WJFM, Bremmers MEJ, Woestenenk R, Bär B, Falkenburg JHF, Kester M, Schaap NPM, Jansen J, Blijlevens NNM, Dolstra H, Huls G. Cruijsen M, et al. Among authors: blijlevens nnm. Biol Blood Marrow Transplant. 2016 Jun;22(6):1000-1008. doi: 10.1016/j.bbmt.2016.02.003. Epub 2016 Feb 6. Biol Blood Marrow Transplant. 2016. PMID: 26860635 Free article.
Low relapse risk in poor risk AML after conditioning with 10-day decitabine, fludarabine and 2 Gray TBI prior to allogeneic hematopoietic cell transplantation.
Cruijsen M, Hilberink JR, van der Velden WJFM, Jansen JH, Bär B, Schaap NPM, de Haan A, Mulder AB, de Groot MR, Baron F, Vellenga E, Blijlevens NNM, Huls G. Cruijsen M, et al. Among authors: blijlevens nnm. Bone Marrow Transplant. 2021 Aug;56(8):1964-1970. doi: 10.1038/s41409-021-01272-3. Epub 2021 Apr 6. Bone Marrow Transplant. 2021. PMID: 33824442 Free article. Clinical Trial.
Long-Term Analysis of Resilience of the Oral Microbiome in Allogeneic Stem Cell Transplant Recipients.
Laheij AMGA, Rozema FR, Brennan MT, von Bültzingslöwen I, van Leeuwen SJM, Potting C, Huysmans MDNJM, Hazenberg MD, Brandt BW, Zaura E, Buijs MJ, de Soet JJ, Blijlevens NNM, Raber-Durlacher JE. Laheij AMGA, et al. Among authors: blijlevens nnm. Microorganisms. 2022 Mar 29;10(4):734. doi: 10.3390/microorganisms10040734. Microorganisms. 2022. PMID: 35456787 Free PMC article.
Development and Validation of a Prediction Model for 1-Year Mortality in Patients With a Hematologic Malignancy Admitted to the ICU.
Boldingh JHL, Arbous MS, Biemond BJ, Blijlevens NMA, van Bommel J, Hilkens MGEC, Kusadasi N, Muller MCA, de Vries VA, Steyerberg EW, van den Bergh WM; Hematologic Malignancy Admitted on the ICU (HEMA-ICU) Study Group. Boldingh JHL, et al. Among authors: blijlevens nma. Crit Care Explor. 2024 May 24;6(6):e1093. doi: 10.1097/CCE.0000000000001093. eCollection 2024 Jun. Crit Care Explor. 2024. PMID: 38813435 Free PMC article.
Risk factors for Nocardia infection among allogeneic hematopoietic cell transplant recipients: A case-control study of the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation.
De Greef J, Averbuch D, Tondeur L, Duréault A, Zuckerman T, Roussel X, Robin C, Xhaard A, Pagliuca S, Beguin Y, Botella-Garcia C, Khanna N, Le Bourgeois A, Van Praet J, Ho A, Kröger N, Ducastelle Leprêtre S, Roos-Weil D, Aljurf M, Blijlevens N, Blau IW, Carlson K, Collin M, Ganser A, Villate A, Lakner J, Martin S, Nagler A, Ram R, Torrent A, Stamouli M, Mikulska M, Gil L, Wendel L, Tridello G, Knelange N, de la Camara R, Lortholary O, Fontanet A, Styczynski J, Maertens J, Coussement J, Lebeaux D. De Greef J, et al. Among authors: blijlevens n. J Infect. 2024 Jun;88(6):106162. doi: 10.1016/j.jinf.2024.106162. Epub 2024 Apr 23. J Infect. 2024. PMID: 38663756 Free article.
Unhealthy lifestyle behaviors, overweight, and obesity among childhood cancer survivors in the Netherlands: A DCCSS LATER study.
Bouwman E, Penson A, de Valk M, van den Oever SR, van der Pal HJH, van Dulmen-den Broeder E, Blijlevens NMA, Bresters D, Feijen EAM, van den Heuvel-Eibrink MM, van der Heiden-van der Loo M, Michel G, Ronckers CM, Teepen JC, Tissing WJE, Versluys BAB, Kremer LCM, Pluijm SMF, Loonen JJ; Dutch LATER Study Group and the PanCareFollowUp Consortium. Bouwman E, et al. Among authors: blijlevens nma. Cancer. 2024 Apr 25. doi: 10.1002/cncr.35338. Online ahead of print. Cancer. 2024. PMID: 38662406
Listeria monocytogenes Infections in Hematopoietic Cell Transplantation Recipients: Clinical Manifestations and Risk Factors. A Multinational Retrospective Case-Control Study from the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation.
Averbuch D, Tridello G, Wendel L, Itälä-Remes M, Oren I, Karas M, Blijlevens N, Beguin Y, Broers A, Calore E, Cattaneo C, Isaksson C, Robin C, Gadisseur A, Maertens J, De Becker A, Lueck C, Metafuni E, Pichler H, Popova M, Ram R, Yeshurun M, Mikulska M, Camara R, Styczynski J. Averbuch D, et al. Among authors: blijlevens n. Transplant Cell Ther. 2024 Apr 15:S2666-6367(24)00346-4. doi: 10.1016/j.jtct.2024.04.008. Online ahead of print. Transplant Cell Ther. 2024. PMID: 38621480
296 results